Hu et al. [47] performed metabolomic analysis to elucidate the metabolic vulnerability of KRAS-mutated lung adenocarcinoma to treatment and reported that the SLC7A11/glutathione pathway exhibits oncogenic KRAS and metabolic synthetic lethality. The gene discussed is KRAS; the disease is lung adenocarcinoma.